GBS News and Press, GBS Inc. From 04/20/21

GBS Inc. (NASDAQ:GBS) traded today at a new 52-week low of $4.16. So far today approximately 622,000 shares have been exchanged, as compared to an average 30-day volume of 247,000 shares. GBS Inc. share prices have moved between a 52-week high of $14.24 and the current low of $4.16 and a...

GBS Inc. (NASDAQ:GBS) traded today at a new 52-week low of $4.19. So far today approximately 622,000 shares have been exchanged, as compared to an average 30-day volume of 247,000 shares. Glucose Biosensor Systems (Greater China) Holdings Inc is a United States based company engaged in m...

GBS ([[GBS]] +4.1%) have received approval from the Harvard Longwood campus Institutional Review Board ((IRB)) to commence a validation study to test clinical samples from a COVID-19 repository.The approval is the first step towards the validation of a rapid POC diagnostic that GBS inten...

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute) have received approval...

Gainers: Immunome (IMNM) +93%, Avinger (AVGR) +33%, Titan Pharmaceuticals (TTNP) +17%, GBS (GBS) +15%, VistaGen Therapeutics (VTGN) +15%.Losers: MEDNAX (MD) -23%, ReWalk Robotics (RWLK) -21%, Shineco (TYHT) -19%,&...

GBS Inc. ([[GBS]] +11.7%) has surged today after announcing a sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to speed up the development of saliva-based diagnostic tests.The research partnership is expected to back the commercialization of two non-invas...

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary health practitioners, today announced the execution of a sponsored research agreement with Jo...

Despite the losses in the morning hours, the recently IPO’ed biosensor diagnostic technology firm GBS Inc. ([[GBS]] +2.9%) is rising after the company announced a collaboration with Wyss Institute for Biologically Inspired Engineering at Harvard University.Per the agreement, ...

GBS (GBS): Q4 GAAP EPS of -$0.23.Revenue of $0.28MPress Release For further details see: GBS reports Q4 results

- December 2020 Initial Public Offering generated $21.6m in gross proceeds and listing on the NASDAQ Stock Market -Executes Partnerships, Research Collaboration and Commercial Agreements- - John Hopkins University, Wyss Institute & Cambridge Consultants Ltd. ...